chrisvoncsefalvay/vaers-outcomes huggingface dataset:
12/17/02 for 11/25/02. Pt called to say that Td from clinic had made her arm very painful, some redness-no temp. Advise warm or cold compress and to check with MD. Advil or pain/antiinflam prn. Then 11-2n I called her for f/u "seems better" with warm comp. and Advil. Still hurts some. Did  not ever call MD. Advise, RTC prn. 1/10/03 pt called to report that her arm is still "sore." Not at the Rt shoulder joint but mid right upper arm. She says that she has limited ROM and pain. She denies redness or swelling and says it does not feel hot to the outside touch, but feels hot to her "inside." Pt says that she has been to her family doctor on 12/17/02 once for this problem. She is taking Rx: Bextra with diagnosis of Bursitis. 1/13/03 I called pt for follow up. She says her arm is a little better, but still sore. She is NKA, has osteoporosis, hypertension and diabetes mellitus. She takes Atlace for HTN and no Rx for diabetes. I explained the VAERS reporting system and told her that we would continue to follow up.
Information has been received from a physician concerning an 11 year old female hispanic student with no allergies, no past medical history and no adverse events following prior vaccinations who in 1998 was vaccinated with a dose of varicella virus vaccine live. There was no illness at the time of vaccination. On 13-Oct-2003, the patient developed chickenpox. The patient had a fever for two days and a rash characterized by papules, vesicles and crusting. Unspecified medical attention was sought, but the patient was not seen by the reporting physician. Laboratory tests were not performed. Subsequently, the patient recovered. A product quality complaint was not involved. Additional information is not expected.
3 weeks pregnant at time of first dose on 12/21/2020. Due date would have been 09/09/2021. Miscarriage on 01/14/2021 at 6 weeks.
Severe body ache, left are around injection site is swollen around the injection site, swelling is spreading to lower arm. upper part of arm is swollen, hot and red. patient reported that she had fever and nausea.
9/29/08 Intussusception - reduced with air contrast enema. 10/08/08-records received for DOS 9/20/08-presented with vomiting, lethargy and cough.  On day of admission began to vomiting 1-15 times and greenish in color with dark material in it. Diapers not wet, decreased urine output. Not interested in drinking. Weight loss, pale with decreased capillary refill and decreased responsiveness to stimulation and pain. Tachycardic, abdomen distended infrequent bowel sounds.Transferred to another facility.  10/08/08-ED report for DOS 10/8/08-C/O lethargy, pale and bilious forming again. Probably recurrent intussusception. Previously hospitalized for intussusception and lung infection on 9/29/08.  10/28/08-records received from receiving facility for DOS 9/30/08 and 10/8-10/9/08-DC DX: Reduced Intussusception.
Pt. complained of neck and arm pain x 3 week; pt was treated with FLEXERIL as needed, and had pt. ice neck & shoulder.
36 hours after the vaccine I developed severe headache, myalgias and fever up to 105 degrees. This has persisted almost daily for over 110 days since the vaccine with fevers from 99.5-104 degrees and an entirely negative fever of unknown origin workup. I have cognitive impairment with the fevers and memory loss. I am struggling to function in daily life and as a telemedicine physician. The final procedure is a lumbar puncture tomorrow based on reports of autoimmune encephalitis. All labs and scans have been entirely normal.
Large, oval shaped red welt on right arm (injection site). Very itchy and hurts to touch,
Brain fog; Inflammation throughout the body; Joint pain; muscle aches; Sensitive skin; This spontaneous case was reported by a consumer and describes the occurrence of CEREBRAL DISORDER (Brain fog), SENSITIVE SKIN (Sensitive skin), INFLAMMATION (Inflammation throughout the body), ARTHRALGIA (Joint pain) and MYALGIA (Muscle aches) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.  No Medical History information was reported.  On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Mar-2021, the patient experienced CEREBRAL DISORDER (Brain fog), SENSITIVE SKIN (Sensitive skin), INFLAMMATION (Inflammation throughout the body), ARTHRALGIA (Joint pain) and MYALGIA (Muscle aches). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Adverse event, at an unspecified dose and frequency and PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, CEREBRAL DISORDER (Brain fog), SENSITIVE SKIN (Sensitive skin), INFLAMMATION (Inflammation throughout the body), ARTHRALGIA (Joint pain) and MYALGIA (Muscle aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.
Swelling/Hard bump at injection site lasting more than 3 days that is warm to the touch, swelling of lymph nodes in left armpit, fatigue, joint pain, muscle aches, fevers, chills, difficulty breathing
RIGHT EAR HAD SLIGHT LOSS OF HEARING/ ALMOST LIKE WATER IN THE EAR; CHILLS; BAD HEADACHE; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. Concomitant medications included ascorbic acid, and zinc.  On an unspecified date, the patient experienced right ear had slight loss of hearing/ almost like water in the ear, chills, and bad headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from right ear had slight loss of hearing/ almost like water in the ear, chills, and bad headache. This report was non-serious.
Loss of erection, severe nausea, dizziness, severe headache, fatigue, chills, severe pain at injection site on arm and armpit, severe itchy rash over half of right arm
acute pancreatitis; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PANCREATITIS ACUTE (acute pancreatitis) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     The patient was thin, athletic and young.     On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PANCREATITIS ACUTE (acute pancreatitis) (seriousness criteria hospitalization and medically significant). At the time of the report, PANCREATITIS ACUTE (acute pancreatitis) outcome was unknown.            No concomitant medications were reported.   The patient was hospitalized twice, the first time for 6 weeks, second time for a little bit less with acute pancreatitis.  No treatment details were reported.  Company comment:  This spontaneous case report concerns a female patient of an unknown age with no medical history or underlying conditions, who experienced serious (medically significant and hospitalization) unexpected event of special interest - Pancreatitis acute. The event occurred after the patient had received the mRNA-1273.222 vaccine (bivalent dose, the exact dose in vaccination schedule was not reported). The onset latency between vaccination and the reported event remained unknown since no dates were provided. As per information provided, the patient was hospitalized twice, the first time for 6 weeks and the second time for a little bit less with acute pancreatitis. At the time of this report, no further information regarding clinical course, laboratory investigations and diagnostic procedures was disclosed. At the time of this report, the outcome of the event remained unknown and treatment medications were not provided. Limited information precludes a meaningful medical assessment at this stage. Case will be re-assessed upon receipt of additional information. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report.
Blood Pressure started  fluctuating (169/122mmHg); Fever 101F; Bad Headache; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD PRESSURE FLUCTUATION (Blood Pressure started  fluctuating (169/122mmHg)), PYREXIA (Fever 101F) and HEADACHE (Bad Headache) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jul-2021, the patient experienced BLOOD PRESSURE FLUCTUATION (Blood Pressure started  fluctuating (169/122mmHg)), PYREXIA (Fever 101F) and HEADACHE (Bad Headache). The patient was treated with LISINOPRIL for Blood pressure fluctuation, at an unspecified dose and frequency. At the time of the report, BLOOD PRESSURE FLUCTUATION (Blood Pressure started  fluctuating (169/122mmHg)), PYREXIA (Fever 101F) and HEADACHE (Bad Headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Blood pressure measurement: 169/122 (High) The patient's blood pressure was 169/122mmHg.. In 2021, Body temperature: 101 (High) The patient's body temperature was 101F..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant product use was provided by the reporter.
This case was reported by a physician and described the occurrence of inappropriate schedule of drug administration in a 6-month-old male subject who was vaccinated with Pediarix for prophylaxis.  Concurrent vaccination included HIB (manufacturer unspecified), Rotateq, Prevnar (manufacturer unspecified) all given on 30 August 2007.  On 30 August 2007 at 10:00 the subject received 3rd dose of Pediarix at 0.5 ml.  First Pediarix was given to the child in June 2007, when the subject was 4 months old.  The 2nd dose of Pediarix was given to the subject in August 2007 and the 3rd dose was given only three weeks after the 2nd dose.  This was considered to be an inappropriate schedule of drug administration.  One day after the 3rd dose of Pediarix, on 31 August 2007, the subject developed fever, was cranky and had a lump on his right thigh.  The fever and crankiness improved.  The outcome of the thigh lump was not known.
It was found after the fact that pt. received his first dose of the Moderna Covid vaccine on 4/28/2021 at our hospital sponsored vaccine clinic at the age of 16. Pt. guardian, grandfather, was contacted and grandfather reports pt. not having any abnormal side effects from the vaccination. Grandfather was instructed to contact hospital once pt. is 18 years of age.
Right redness, slight swelling and slight pain for 2 days. Per patient's mother, patient has history of allergic reactions to immunizations. Notified of this today. 11/14/2002
The patient was given a Moderna Covid-19 vaccine accidentally instead of a Pfizer Covid-19 vaccine. This Moderna vaccine was given on 1/28/21, which was 22 days after an initial Pfizer Covid-19 vaccine was given on 1/6/21. The patient developed a fever less than 24 hours following the event.
Mother returned on 08/14/2023 for a different reason and mentioned that her child, who was vaccinated 08/11/2023, had experienced swollen eyes and fever the night of 08/11/2023. Mother knew fever was expected but concerned about the swollen eyes. Mother reports this symptom last until 08/13/2023. Mother reported no other symptoms.
Moderna COVID-19 Vaccine: Headache, chills, mild fever 99.9 F, and extreme sore arm and shoulder. Unable to grip items  with hand. Arm was not usable for about 36 hours. Could not lift arm on my own and any movement of arm, even slight sent radiating pain throughout arm and shoulder. Arm felt dead like a nerve problem but was very painful.
Child's back covered with red dots and white centers which are nickle size on chest not as many but they are dime size. Denies any fever.
Information has been received from a medical assistant referring to a patient of unknown age and gender. Information about concurrent condition, concomitant medication and medical history was not provided. On 04-FEB-2019, the patient was vaccinated with improperly stored PEDVAXHIB (1 injection, via intramuscular, lot # reported as: R0123571, expiration date: 19-MAR-2021; strength and anatomical location were not reported) for prophylaxis. No adverse effect was reported. The PEDVAXHIB was exposed to 0 degree Celsius for 45 minutes. There was no previous temperature excursion. The data logger was involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1902USA008818: US-009507513-1903USA006922: US-009507513-1903USA006923: US-009507513-1903USA006924: US-009507513-1903USA006925: US-009507513-1903USA006926: US-009507513-1903USA006927: US-009507513-1903USA006928: US-009507513-1903USA006929: US-009507513-1903USA006930: US-009507513-1903USA006931: US-009507513-1903USA006932: US-009507513-1903USA006933: US-009507513-1903USA006935: US-009507513-1903USA006936: US-009507513-1903USA006937: US-009507513-1903USA006938: US-009507513-1903USA006939: US-009507513-1903USA006940: US-009507513-1903USA006941: US-009507513-1903USA006942: US-009507513-1903USA006943: US-009507513-1903USA006944: US-009507513-1903USA006945: US-009507513-1903USA006946: US-009507513-1903USA006947: US-009507513-1903USA006948: US-009507513-1903USA006949: US-009507513-1903USA006950.
NP placed HepB immunization order for 25 yo patient in EMR. MA administered 10 mcg/0.5 mL dose to patient. MA did not scan medication prior to administration and when during documentation was wondering why EMR was not accepting the NDC that was administered to patient. Appropriate HepB dose/product for a 25 yo is 20 mcg/1 mL, thus the 10 mcg/0.5 mL did not match the order placed. Patient was able to be returned back to clinic to receive full dose.
Pt tested positive for COVID 5/28/21. Completed COVID vaccine series 1/18/21. Symptom onset 5/27/21. Was also COVID positive 10/12/2020.
This spontaneous report as received from a pharmacist via a company representative refers to a 46 year old male patient. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions, or allergies was provided. On 06-JUL-2017, the patient was vaccinated expired dose of M-M-R II, (lot # not reported expiration 01-JUL-2017) for prophylaxis. No adverse event reported. No additional information reported. Additional information has been requested.
warm; about 3 inches by 2 inches pink area; redness; red bumps; itching; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (red bumps), PRURITUS (itching), SKIN WARM (warm), SKIN DISCOLOURATION (about 3 inches by 2 inches pink area) and ERYTHEMA (redness) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, the patient experienced RASH ERYTHEMATOUS (red bumps), PRURITUS (itching) and ERYTHEMA (redness). On 15-Feb-2021, the patient experienced SKIN WARM (warm) and SKIN DISCOLOURATION (about 3 inches by 2 inches pink area). On 14-Feb-2021, RASH ERYTHEMATOUS (red bumps) and ERYTHEMA (redness) had resolved. At the time of the report, PRURITUS (itching) had not resolved and SKIN WARM (warm) and SKIN DISCOLOURATION (about 3 inches by 2 inches pink area) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
Immediately after discharge from the emergency department, the patient noted hives to the right neck and numbness to her face.  She fell asleep at 3am on 10/17/20 and woke at approximately 8:30am on 10/17/20 with numbness to the right side of her body.  This resolved by the time she arrived at the emergency department at 1049am.
Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Systemic: Fever-Medium, Systemic: Joint Pain-Severe, Systemic: Weakness-Severe, Additional Details: Patient experienced a reaction after receiving the shot. It was a delayed reaction and the patient reported severe pain and swelling to the injection area. Pain radiated throughout the arm and the arm was very hot. Patient went to see her primary care physician 6 days later due to the adverse effects that she experienced from the vaccination.
Facial swelling and rash left shoulder, treated with DEPO-MEDROL intramuscularly, PREDNISONE series, seen in follow up 06/28/2006, 06/29/2006 and 07/03/2006.  Episode may have been poison ivy.
2ND ACHY. DAY AFTER INJECTION. RAN FEVER 101.6. BECAME CONFUSED. GROUND GLASS COUGH, VENTRICULAR TACHYCARDIA. ADMITTED TO HOSPITAL. IV STEROIDS,AND  ANTIBIOTIC STARTED. CHANGED TO PO AFTER 3 DAYS. PT IMPROVED. COUGH RESOLVED PT SENT HOME WITH ORAL STEROIDS AND ANTIBIOTICS FOR 3 DAYS.
Information has been received from a physician concerning a female patient who on approximately 27-DEC-2009 was vaccinated with the second dose of GARDASIL (lot #, route and site of administration not reported). Concomitant vaccination included ADACEL. On approximately 27-DEC-2009 ("sometime last week") the patient passed out after vaccination. The patient stayed in the clinic for 4 hours before the office allowed her to go home. At the time of this report, the patient had recovered. Follow up information has been received concerning a 16 year old female student who on 31-DEC-2009, at 9:45, was vaccinated with the first dose of GARDASIL (lot# 662304/1013Y) into her right arm. On 31-DEC-2009, at 9:44, the patient was vaccinated with the first dose of ADACEL (lot #C33838A) into her left arm. On 31-DEC-2009, at 9:45, the patient became faint and dizzy following administration of vaccines. The patient was given juice, lying down with feet elevated. On an unspecified date, the patient recovered. Additional information is not expected.
stabbing joint pain; headache; vivid dreams; brain fog; Lymphadenopathy; malaise; tiredness; chills; fever of 101F; Muscle pain/Muscle aches; booster; This is a spontaneous report from a contactable Consumer (Patient) . A 44-year-old non pregnant female patient received third dose of BNT162B2 (BNT162B2, Solution for injection, Lot number: FF8841) via unspecified route on right arm on 15Nov2021 1:00 PM as dose 3 (booster), single for covid-19 immunisation (age at vaccination: 44-years-old). The patient's medical history included Asthma. Concomitant medications were not reported. The patient received 1st dose of BNT162B2 on 26Jan2021 (lot number: EL3247) and dose 2 on 16Feb2021 11::00 AM  (lot number: EL3247) on left arm for covid-19 immunisation (age at 43-years-old). On 16Nov2021 04:00 AM, patient had  stabbing joint pain, headache, vivid dreams. On 15Nov2021 7:00 PM, patient had  Lymphadenopathy, muscle aches, chills, fever of 101F, malaise, tiredness, brain fog. Lymphadenopathy still persists. No Covid prior vaccination, not tested for Covid post vaccination, No other vaccine in four weeks, Other medications in two weeks was No. No treatment received for the events. Outcome of all events was recovering.  Follow-Up (23Nov2021): Follow-up attempts are completed. No further information is expected.
8/9: Admitted to transplant service with dehydration, hypotension, and leukopenia after presenting to transplant clinic for scheduled visit. Found to be COVID-19 positive. Was placed in isolation with plan to monitor O2.  8/14: Patient became symptomatic. Tachycardic and SpO2 upper 80s% on room air on AM of 08/14/2021.; STAT CXR and ABG ordered 08/14/2021. 8/19: Remdesivir 200 mg IV x 1 and then 100 mg daily (days 2-5); advanced to Dexmethasone 6 mg PO daily per primary team;  addition of Cefepime 1 g q 12 hours to cover post-viral HAP  8/20: Pulmonary reports:  1. Acute Hypoxic Respiratory Failure - Secondary to Covid-19 PNA. Noncontrast CT changes c/w covid-19 PNA. No evidence of pulmonary edema; however, in setting of covid-19 it is appropriate to diurese to maintain net negative to net even fluid balance based on ARDS management.  2. Covid-19 Pneumonia in Immunocompromised Patient - Currently receiving Cyclophosphamide and Remicade q8 weeks (daily Prednisone switched to Dexamethsone due to covid). Covid-19 positive on 8/9. Continue Dexamethasone 6mg daily and Remdesivir per ID recommendations. Oxygen requirements have increased, and he is now requiring HFNC (although still on minimal settings, currently 20L, 50%). Diuresis as above will help to optimize respiratory status. Continue oxygen supplementation to maintain saturations >90%.  8/21: Admitted to ICU due to increasing oxygen requirement on high flow nasal cannula in the setting of COVID-19 infection.  8/27: transferred out of ICU 9/2: CT chest showed expanding right sided pTX 9/3:  chest tube placed; transferred to ICU - Patient had worsening O2 requirements shortly after chest tube placement  - VQ scan demonstrated low probability of PE; duplexes BUE/BLE negative - Completed 3-day empiric Cefepime for HAP - Thoracic surgery discontinued chest tube on 9/9 - 9/9 CXR: after removal of chest tube, No pneumothorax. No pleural effusions 9/14: transferred out of ICU 9/21: Now doing well on 1L via NC and anticipate that patient will be weaned off completely soon; Plan to discharge to acute rehab facility within next two days
Fever (up to 102F), chills, slight nausea, tension headache on upper neck, restlessness, joint pain, all beginning around 5pm. Went to sleep at 8-10pm (challenges sleeping). Woke up at 8am with 99.0F temp. Showered. Back to 97.6 by 10am.
This spontaneous report as received from a medical assistant referring to five patients of unknown age and gender. On an unknown date, the patients were vaccinated with M-M-R II lot # M039913, expiration date 62-SEP-2018 for prophylaxis, reconstituted with sterile diluent (manufacturer unknown). On an unspecified date, the vaccines and sterile diluent (manufacturer unknown) were exposed to temperature ranges between 47° Fahrenheit (F) to 77°F during a time frame of 12 hours 30 minutes. There was not previous temperature excursion. The temperature excursion was not called by a data logger. Adverse effects were not reported.